rs28634651 — ZFPM1

ZFPM1 rs28634651 — A Transcription Factor Rheostat for Platelet Production

Every platelet in your bloodstream is pinched off from a giant bone-marrow cell called a megakaryocyte¹¹ megakaryocyte
megakaryocytes are polyploid precursor cells that extend long cytoplasmic projections called proplatelets into bone-marrow sinusoids; platelets bud from these extensions at a rate of roughly 100 billion per day in a healthy adult. The process that turns a stem cell into a mature platelet-producing megakaryocyte is governed by an intricate transcriptional program, and at its center sits the partnership between GATA-1 and its cofactor FOG1²² GATA-1 and its cofactor FOG1
GATA-1 (encoded by GATA1) is a zinc-finger transcription factor that recognizes (A/T)GATA(A/G) motifs; FOG1 (Friend Of GATA-1, encoded by ZFPM1) binds the N-terminal zinc finger of GATA-1 and recruits the NuRD chromatin-remodeling complex to regulate target gene activity. The rs28634651 C variant sits in the first intron of ZFPM1 — a regulatory address that shapes how much FOG1 protein is available at the critical moment of megakaryocyte maturation.

The Mechanism

rs28634651 (NC_000016.10:g.88486790T>C) is located 747 bases into the first intron of ZFPM1 at chromosome 16q24.2. Intronic variants in this position commonly act as intronic splicing regulators or enhancer elements³³ intronic splicing regulators or enhancer elements
deep intronic variants can create or destroy branch-point sequences, polypyrimidine tracts, or intronic enhancer binding sites for transcription factors; they alter mRNA abundance, splicing efficiency, or isoform balance without changing the protein's amino acid sequence. The C allele of rs28634651 is associated with altered ZFPM1 expression in hematopoietic progenitors, most likely by perturbing an intronic regulatory element that fine-tunes FOG1 levels during the megakaryocytic commitment step.

FOG1 is not an independent transcription factor — it has no DNA-binding activity of its own. It works exclusively by clamping onto GATA-1's N-terminal zinc finger⁴⁴ GATA-1's N-terminal zinc finger
the GATA-1/FOG1 protein-protein interaction is essential: GATA-1 mutations that prevent FOG1 binding cause severe congenital macrothrombocytopenia in humans and redirecting the GATA-1 complex from activating to repressing target genes, or from one chromatin-remodeling complex to another. The FOG1-NuRD sub-complex is specifically required for normal α-granule biogenesis and P-selectin loading⁵⁵ normal α-granule biogenesis and P-selectin loading
mice with disrupted FOG1-NuRD interaction have macrothrombocytopenia with few α-granules and absent P-selectin; thrombin stimulation fails to trigger Akt phosphorylation, resulting in defective granule secretion and platelet aggregation. Subtle changes in FOG1 dosage — the kind an intronic regulatory variant produces — therefore alter not just platelet count but platelet reactivity and activation signaling.

The Evidence

Astle et al. Cell 2016⁶⁶ Astle et al. Cell 2016
"The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease" — GWAS of 29.5 million variants in 173,480 participants across 36 blood cell phenotypes identified multiple independent signals in the ZFPM1 locus (16q24.2) at genome-wide significance for platelet count (p=10⁻¹⁹ for rs59865663; β=+0.041 SD), plateletcrit (p=10⁻¹⁹), and several red cell and eosinophil indices — consistent with FOG1's dual role in megakaryocytic and erythroid lineage commitment. The ZFPM1 locus GWAS signal for platelet count is among the largest-effect platelet loci in the human genome.

Two large VTE GWAS studies have converged on the ZFPM1 region as a contributor to venous thromboembolism risk through platelet-mediated mechanisms. Thibord et al. Circulation 2022⁷⁷ Thibord et al. Circulation 2022
"Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors" — 81,669 VTE cases across 30 studies, 135 independent loci identified; novel loci included platelet-function genes beyond classic coagulation cascade components and Ghouse et al. Nature Genetics 2023⁸⁸ Ghouse et al. Nature Genetics 2023
"Genome-wide meta-analysis identifies 93 risk loci and enables risk prediction equivalent to monogenic forms of venous thromboembolism" — 81,190 cases, 1.4 million controls; 62 previously unreported loci; PRS top 0.1% equivalent to monogenic F2/F5 carriers both identified coagulation-independent, platelet-convergent loci in this region, supporting the biological model that platelet count and reactivity — not only coagulation cascade function — contribute meaningfully to thrombotic risk.

The mechanistic basis is established in animal models: FOG1-deficient mice completely fail to produce megakaryocytes or erythrocytes⁹⁹ completely fail to produce megakaryocytes or erythrocytes
Mancini et al. EMBO J 2012 — FOG-1 loss causes progenitors to reprogram toward myeloid identity; FOG-1 is required upstream of GATA-1 in lineage specification, not just downstream, and partial FOG1 reduction produces quantitative platelet deficits. The clinical relevance of the rs28634651 regulatory signal therefore sits in the space between these extremes: not disease-causing, but shifting the platelet production set-point in a direction that interacts with other thrombotic risk factors.

Practical Actions

Carriers of one or two C alleles have modestly elevated platelet counts and potentially increased baseline platelet reactivity. The primary clinical implications are (1) awareness that standard platelet count ranges may underestimate true reactivity for C-allele carriers, and (2) that other thrombotic risk factors — prolonged immobility, oral contraceptives with high-dose estrogen, factor V Leiden or prothrombin variant co-carriage — compound onto an already-calibrated-high platelet baseline.

For CC homozygotes, platelet reactivity monitoring is a reasonable precaution when planning extended high-risk scenarios (long-haul flights, major surgery, hormonal therapy initiation). Omega-3 fatty acids (EPA/DHA) directly modulate platelet phospholipid composition and reduce thromboxane A₂-driven aggregation — a specific, genotype-relevant strategy for individuals with elevated platelet reactivity.

Interactions

The ZFPM1/FOG1 pathway interacts with coagulation factor variants at the network level: carriers of rs28634651 C who also carry the Factor V Leiden variant (rs6025, FV G1691A) or prothrombin G20210A (rs1799963) face compounded thrombotic risk through independent platelet and coagulation pathways. This has not been formally studied in combination for rs28634651 specifically, but the biological independence of the two mechanisms (platelet reactivity vs. thrombin generation) means risk is additive rather than redundant.

VEGF signaling also intersects with FOG1 biology: the ZFPM1 locus GWAS signal rs8045833 is associated with VEGF levels (β=−0.108 SD, p=10⁻⁷), suggesting that ZFPM1 regulatory variation affects not only platelet production but endothelial-platelet cross-talk through VEGF-mediated pathways.